Comparative Pharmacology
Head-to-head clinical analysis: TOLTERODINE TARTRATE versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOLTERODINE TARTRATE versus VESICARE LS.
TOLTERODINE TARTRATE vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5) with relative selectivity for the bladder over salivary glands. Reduces detrusor muscle contractility and bladder pressure.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
2 mg orally twice daily. May be reduced to 1 mg orally twice daily based on tolerability.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in extensive metabolizers (CYP2D6) and approximately 9 hours in poor metabolizers. In clinical context, dosing interval is adjusted in poor metabolizers (e.g., 2 mg twice daily reduced to 2 mg once daily).
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Renal (77%) and fecal (17%): approximately 14% as unchanged tolterodine, 51% as the active 5-hydroxymethyl metabolite, and 12% as other metabolites. Biliary excretion contributes minimally.
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category A/B
Category C
Anticholinergic
Anticholinergic